Eton Pharmaceuticals, Inc. is a Deer Park, Illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway. Our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.
Location: United States, Illinois
Employees: 11-50
Total raised: $20M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | SWK Holdin... | swkhold.co... |
| 05.08.2026 | Runway Gro... | runwaygrow... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.06.2017 | Series A | $20M | - |
Mentions in press and media 13
| Date | Title | Description |
| 26.08.2026 | Cramer’s lightning round: Buy QXO | Monday - Friday, 6:00 - 7:00 PM ET It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed. BillionToOne: “We decided it’s a pretty dar... |
| 13.12.2024 | Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases | Angitia Biopharmaceuticals – a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases – announced the closing of a $120 million Series C financing round. Bain ... |
| 05.08.2024 | Relief Therapeutics secures up to $11 million | Relief Therapeutics, which focuses on the development and commercialization of patent-protected drugs for rare and ultra-rare diseases, announced the signing and closing of a definitive agreement with SWK Funding LLC (SWK), a wholly-owned ... |
| 02.04.2024 | A positive growth trajectory for three pharmaceutical startups | Based in Basel, Santhera has pipeline of drugs for neuromuscular and pulmonary diseases that currently lack treatment options. Their drug candidate AGAMREE® (vamorolone) is a first-in-class dissociative steroid with novel mode of action, wh... |
| 16.11.2021 | Eton Pharmaceuticals : Reports Third Quarter Financial Results - Form 8-K | Eton Pharmaceuticals Reports Third Quarter Financial Results DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatmen... |
| 16.11.2021 | Eton Pharmaceuticals Reports Third Quarter Financial Results | DEER PARK, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for t... |
| 10.11.2021 | Q3-2021 Letter to Stockholders | Harrow Health, Inc. Letter to Stockholders November 9, 2021 To the Stockholders of Harrow Health, Inc.: I am pleased to provide our stockholders with the good news that our team has delivered strong top-line revenue and year-over-year earni... |
| 16.08.2021 | Eton Pharmaceuticals : Reports Second Quarter Financial Results | DEER PARK, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for t... |
| 16.08.2021 | Eton Pharmaceuticals : Reports Second Quarter Financial Results (Form 8-K) | Eton Pharmaceuticals Reports Second Quarter Financial Results DEER PARK, Ill., Aug 16, 2021 (GLOBE NEWSWIRE) - Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatmen... |
| 10.08.2021 | Harrow Health : Q2-2021 Letter to Stockholders | Harrow Health, Inc. Letter to Stockholders August 10, 2021 To the Stockholders of Harrow Health, Inc.: Harrow continues to be a reliable and innovative pharmaceutical supplier to hundreds of thousands of Americans and many thousands of eyec... |
Show more